We have come to rely on Genedata Expressionist as the leading bioinformatics tool.
Tokyo, Japan (PRWEB) July 11, 2011
Genedata, a leading provider of advanced software solutions for drug discovery and life science research, today announced it has become a member of the Netherlands Toxicogenomics Centre (NTC). NTC uses toxicogenomics to advance the understanding of toxicological mechanisms and provide more humane alternatives to animal testing in the development of drug therapies, cosmetics, and chemicals. This research has been enabled by NTC’s collaboration with Genedata, and NTC’s use of Genedata Expressionist. Genedata Expressionist provides a software platform for research into the impact of toxins on cells and organisms. Genedata Expressionist 7.0 will be featured at the 38th Annual Meeting of the Japanese Society of Toxicology (JSOT) conference (July 11-13).
“Our research is moving away from animal testing, which is increasingly costly and can be highly unreliable, and moving towards in silico toxicogenomics,” said Prof. Dr. Jos Kleinjans, scientific director of NTC. “Therefore, the NTC requires outstanding bioinformatics tools capable of handling a range of omics data. We have come to rely on Genedata Expressionist as the leading bioinformatics tool for processing and visualizing omics data and we view Genedata as an innovative partner who understands how to collaborate with large consortia such as the NTC.”
Genedata Expressionist gives the NTC a single platform on which to conduct and share carcinogenomics and toxicogenomics research. Easily handling extremely large data sets and studies, it provides comprehensive analysis and management of the complete transcriptome, genome, methylome, proteome, and metabolome. With an open and scalable architecture, the system supports all major vendors and technology platforms enabling researchers to optimize technology investments. As a communications platform, Genedata Expressionist helps to bridge the gap between biology and statistics with advanced statistical tools and shared sessions. And, its graphical analysis workflows allow interdisciplinary teams to easily collaborate and increase efficiency.
Genedata Expressionist Helps to Enable Humane Research Methodology
NTC research projects seek to develop tests that require fewer laboratory animals or cause them less inconvenience. “The integration of data and bioinformatics tools enables safer approaches to advancing the development of pharmacologic, cosmetics, and chemical products,” continued Kleinjans, “and may eventually replace animal tests completely by in vitro assays using animal or human cells.”
The NewGeneris and carcinoGENOMICS, funded by the European Union, demonstrate additional in silico toxicogenomics research projects using Genedata Expressionist. carcinoGENOMICS is developing in vitro methods for assessing the carcinogenic potential of compounds as an alternative to rodent bioassays for genotoxicity and carcinogenicity. The NewGeneris project is researching the role of prenatal and early-life exposure to genotoxic chemicals in food and the environment and the connection to childhood cancer and immune disorders. These investigations seek to identify biomarkers that indicate exposure to toxic chemicals or their biological effects. In both the NewGeneris and carcinoGENOMICS projects, Genedata Expressionist helps to manage the vast amount of genomics, transcriptomics, and proteomics data.
“Since 2006, Genedata has been working with the NTC research partner community,” said Dr. Othmar Pfannes, CEO of Genedata. “These long-standing alliances help Genedata to continuously innovate and support emerging life-saving technologies. Genedata membership in NTC underscores the value of this alliance and a future commitment to advancing this successful relationship.”
Genedata transforms data into intelligence with a portfolio of advanced software solutions for drug discovery and life science research, which spans target, lead, and biomarker discovery. Used by a majority of the world’s top 50 pharmaceutical companies and leading research organizations, Genedata Phylosopher®, Genedata Screener®, Genedata Expressionist®, Genedata Analyst™, Genedata Selector™, and Genedata Biologics™ make research data accessible and understandable, enabling scientific discovery that fights disease and improves health worldwide. Founded in 1997, Genedata is privately held, with headquarters in Basel, Switzerland, and offices in Japan, Germany, and the US. http://www.genedata.com.